KRYS
Krystal Biotech, Inc.
NASDAQ · Healthcare · Biotechnology · US
$332.29
+2.38%Year over year
Reported trailing growth
- Revenue
- +22.6%
- EBITDA
- +27.2%
- EBIT
- +42.1%
- EPS
- +62.2%
- Free cash flow
- +39.0%
- Operating cash flow
- +39.4%
Forward estimates
Based on analyst estimates
- Revenue
- +33.4%
- EBITDA
- +52.7%
- EPS
- +1.5%
Three-year CAGR
- Revenue
- +177.0%
- EBITDA
- +78.3%
- EBIT
- +145.5%
- Net income
- +332.9%
- EPS
- +320.7%
- Free cash flow
- +58.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026